Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 4;12(1):e0169400.
doi: 10.1371/journal.pone.0169400. eCollection 2017.

Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI)

Oliver Königsbrügge  1 , Florian Posch  1   2 , Marlies Antlanger  3 , Josef Kovarik  4 , Renate Klauser-Braun  5 , Josef Kletzmayr  5 , Sabine Schmaldienst  6 , Martin Auinger  7 , Günther Zuntner  8 , Matthias Lorenz  9 , Ella Grilz  1 , Gerald Stampfel  1 , Stefan Steiner  1 , Ingrid Pabinger  1 , Marcus Säemann  3 , Cihan Ay  1   10
Affiliations

Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI)

Oliver Königsbrügge et al. PLoS One. .

Abstract

Background: Atrial fibrillation (AF) adds significant risk of stroke and thromboembolism in patients on hemodialysis (HD). The aim of this study was to investigate the prevalence of AF in a population-based cohort of HD patients and practice patterns of antithrombotic therapy for stroke prevention in AF.

Methods: The Vienna InVestigation of AtriaL fibrillation and thromboembolism in patients on hemodialysis (VIVALDI), an ongoing prospective observational cohort study, investigates the prevalence of AF and the risk of thromboembolic events in HD patients in Vienna, Austria. We analyzed cross-sectional data of 626 patients (63.4% men, median age 66 years, approx. 73% of HD patients in Vienna), who provided informed consent. A structured interview with each patient was performed, recent and archived ECGs were viewed and medical histories were verified with electronic records.

Results: The overall prevalence of AF was 26.5% (166 patients, 71.1% men, median age 72 years) of which 57.8% had paroxysmal AF, 3.0% persistent AF, 32.5% permanent AF, and 6.6% of patients had newly diagnosed AF. The median CHA2DS2-VASc Score was 4 [25th-75th percentile 3-5]. In multivariable analysis, AF was independently associated with age (odds ratio: 1.05 per year increase, 95% confidence interval: 1.03-1.07), male sex (1.7, 1.1-2.6), history of venous thromboembolism (2.0, 1.1-3.6), congestive heart failure (1.7, 1.1-2.5), history of or active cancer (1.5, 1.0-2.4) and time on HD (1.08 per year on HD, 1.03-1.13). Antithrombotic treatment was applied in 84.4% of AF patients (anticoagulant agents in 29.5%, antiplatelet agents in 33.7%, and both in 21.1%). In AF patients, vitamin-K-antagonists were used more often than low-molecular-weight heparins (30.1% and 19.9%).

Conclusions: The prevalence of AF is high amongst HD patients and is associated with age, sex, and distinct comorbidities. Practice patterns of antithrombotic treatment indicate a lack of consensus for stroke prevention in HD patients with AF.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow chart of the patient recruitment.
Fig 2
Fig 2. Prevalence of atrial fibrillation in patients with increasing age and time on hemodialysis.
Fig 3
Fig 3. Distribution of patients with AF across CHA2DS2-VASc Scores and frequency of corresponding anticoagulation treatment.
Fig 4
Fig 4. Distribution of patients with AF across HAS-BLED Scores and frequency of corresponding anticoagulation treatment.
See this image and copyright information in PMC

References

    1. Go A, Hylek E, Phillips K. Prevalence of diagnosed atrial fibrillation in adults. JAMA. 2001;285: 2370–2375. - PubMed
    1. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386: 154–162. 10.1016/S0140-6736(14)61774-8 - DOI - PMC - PubMed
    1. Shih C-J, Ou S-M, Chao P-W, Kuo S-C, Lee Y-J, Yang C-Y, et al. Risks of Death and Stroke in Patients Undergoing Hemodialysis With New-Onset Atrial Fibrillation: A Competing-Risk Analysis of a Nationwide Cohort. Circulation. 2016;133: 265–272. 10.1161/CIRCULATIONAHA.115.018294 - DOI - PubMed
    1. Genovesi S, Vincenti A, Rossi E, Pogliani D, Acquistapace I, Stella A, et al. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis. 2008;51: 255–262. 10.1053/j.ajkd.2007.10.034 - DOI - PubMed
    1. Molnar AO, Bota SE, Garg AX, Harel Z, Lam N, McArthur E, et al. The Risk of Major Hemorrhage with CKD. J Am Soc Nephrol. 2016;27: ePub ahead of print. - PMC - PubMed